Clinical trials investigating neoadjuvant and adjuvant strategies in resectable NSCLC with other actionable molecular alterations including KRAS, ROS1, and RET are currently underway and may yield data that aid in the selection of patients for targeted therapy approaches [57] The role of other nonactionable molecular alterations such as STK 11, KEAP1, and TP53 mutations and other known markers of poor responses to ICIs in determining the appropriateness of neoadjuvant immunotherapies vs. adjuvant and perioperative approaches is another area for investigation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.